Related Experiment Video
Updated: Oct 27, 2025
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
The Rise of the TROP2-Targeting Agents in NSCLC: New Options on the Horizon
Yasar Ahmed1, Jose Javier Berenguer-Pina1, Thamir Mahgoub2
1Medical Oncology Department, St. Vincent's University Hospital, Dublin, Ireland.
Background:
Lung cancer is the most common thoracic malignancy, representing the leading cause of cancer-related deaths worldwide with a 5-year survival rate of <10%.
Summary:
The emergence of targeted therapy and immunotherapy has changed the treatment paradigm of advanced non-small cell lung cancer (NSCLC). However, for those who are not eligible for such therapy or currently have no available standard treatment options, new precision treatment approaches are needed. Human trophoblast cell-surface antigen 2 (TROP2) is a transmembrane glycoprotein that is highly expressed on several epithelial tumours including NSCLC. TROP2 is recognized as a promising molecular target for therapeutic development in various types of TROP2-expressing malignancies. As a result, several TROP2-targeted therapeutics have recently been developed for clinical use, such as anti-TROP2 antibodies and TROP2-targeted antibody-drug conjugates. Key Message: This review explores the literature data on the role of TROP2 in cancer development and the potential use of emerging TROP2 antibody-drug conjugates in NSCLC treatment.
Insights
New precision treatments targeting Human trophoblast cell-surface antigen 2 (TROP2) are needed for advanced non-small cell lung cancer (NSCLC). This review explores TROP2
Area of Science:
- Oncology
- Molecular Biology
- Drug Development
Background:
- Lung cancer is a leading cause of cancer deaths globally.
- Advanced non-small cell lung cancer (NSCLC) survival rates remain low.
- Novel therapeutic targets are crucial for improving NSCLC outcomes.
Purpose of the Study:
- To review the role of TROP2 in cancer development.
- To explore the potential of TROP2-targeted therapies for NSCLC.
- To summarize emerging TROP2 antibody-drug conjugates for NSCLC treatment.
Main Methods:
- Literature review of TROP2 in cancer.
- Analysis of TROP2 expression in NSCLC.
- Evaluation of TROP2-targeted therapeutics, including antibody-drug conjugates.
Main Results:
- TROP2 is highly expressed in various epithelial tumors, including NSCLC.
- TROP2 is a promising molecular target for therapeutic development.
- Several anti-TROP2 antibodies and antibody-drug conjugates are in clinical development.
Conclusions:
- Targeted therapies and immunotherapies have advanced NSCLC treatment.
- New precision approaches are needed for patients ineligible for current therapies.
- TROP2-targeted antibody-drug conjugates represent a promising avenue for NSCLC treatment.
More Related Videos
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistant Cancers